USPTO Examiner CRONIN JOHN MICHAEL - Art Unit 1658

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18434731DRY POWDER FORMULATION OF CAVEOLIN-1 PEPTIDES AND METHODS OF USE THEREOFFebruary 2024December 2024Allow1110YesNo
18385771TREATMENT OF HPV INFECTIONOctober 2023November 2024Abandon1310NoNo
18069541MODIFIED PEPTIDE FRAGMENTS OF CAV-1 PROTEIN AND THE USE THEREOF IN THE TREATMENT OF FIBROSISDecember 2022May 2023Allow500YesNo
17934896Methods of Suppression and Treatment of Disease Comprising administering Bicycle Peptide Ligands Specific for EphA2September 2022July 2023Allow1000YesNo
17822161ANTIMICROBIAL PEPTIDES AND RELATED METHODSAugust 2022February 2024Allow1820YesNo
17816954ANTICANCER PEPTIDE AND USE THEREOF FOR INHIBITING CANCER CELL VIABILITYAugust 2022October 2023Abandon1510YesNo
17864702Methods of Treating Alzheimer's DiseaseJuly 2022November 2024Abandon2830NoNo
17810404MNK INHIBITORS AND EIF4E PHOSPHORYLATION MODULATION TO TREAT INFLAMMATORY PAIN IN THE AGEDJuly 2022August 2023Abandon1410NoNo
17846227Method of Preparing Crosslinked Hydrogels, Resulting Muscle Stem Cell Culture Media, and Methods of Use.June 2022February 2023Allow811NoNo
17731312ATOPIC DERMATITIS THERAPY WITH KAPPA OPIOID RECEPTOR AGONIST AS ADJUNCT TO TOPICAL CORTICOSTEROIDApril 2022January 2025Abandon3321NoNo
17727276ICD PEPTIDE AND USE THEREOF FOR HAVING CYTOTOXIC ACTIVITY ON CANCER CELLSApril 2022November 2023Abandon1811NoNo
17722081COMPOSITIONS AND METHODS OF USE OF SYNTHETIC PEPTIDES WITH MYCOBACTERIUM ABSCESSUS INHIBITORY ACTIVITYApril 2022May 2023Allow1301YesNo
17707332INHIBITION OF TUMOR NECROSIS FACTOR, PRO-INFLAMMATORY CYTOKINES AND OTHER IMFLAMMATORY RESPONSE MEDIATORSMarch 2022April 2024Abandon2511NoNo
17680271BVP10 PROTEIN FOR CONTROLLING TETRANYCHID MITES AND USE THEREOFFebruary 2022September 2023Allow1810YesNo
17678403METHOD OF ADMINISTERING A DUAL THERAPEUTIC AND COSMETIC AGENTFebruary 2022May 2024Abandon2620NoNo
17456628FORMULATIONS FOR TREATING CRAMPS AND SPASMSNovember 2021November 2024Allow3520NoNo
17602750APPETITE SUPPRESSION WITH PHARMACEUTICAL COMPOSITIONS CONTAINING BIGLYCAN AS AN ACTIVE INGREDIENTOctober 2021March 2024Allow2920YesNo
174094333D PHARMACOPHORE MODEL FOR THE RAPID COMPUTATIONAL SCREENING OF SARS-COV-2 MODULATORS AND COMPOSITIONS AND METHODS THEREOFAugust 2021August 2023Abandon2410NoNo
17388846METHOD OF PROGNOSIS OF BRONCHOPULMONARY DYSPLASIA IN PREMATURE INFANTSJuly 2021January 2025Abandon4121YesNo
17311789AN IMPROVED PROCESS FOR THE PREPARATION OF PLECANATIDEJune 2021August 2024Allow3810YesNo
17295360LIPO-GLYCOPEPTIDE CLEAVABLE DERIVATIVES AND USES THEREOFMay 2021April 2024Abandon3501NoNo
17288197ANTI-OBESITY AGENT, POLLAKIURIA IMPROVING AGENT, AND AUTONOMIC NERVOUS ACTIVITY REGULATORApril 2021August 2024Allow4021YesNo
17284343PEPTIDE FOR COSMETIC APPLICATIONApril 2021May 2024Abandon3730YesNo
17223629NOVEL ARID5A PEPTIDE INHIBITORSApril 2021August 2023Allow2820NoNo
17215089METHOD OF TREATING VIRAL INFECTIONSMarch 2021February 2023Abandon2310NoNo
17278532ANTI-MICROBIAL PEPTIDESMarch 2021August 2024Allow4121YesNo
17277783METHODS OF PHYSICOCHEMICAL-GUIDED PEPTIDE DESIGN AND NOVEL PEPTIDES DERIVED THEREFROMMarch 2021June 2023Abandon2601NoNo
17203126LIQUID FORMULATIONS OF GLUCAGON ANALOGUESMarch 2021January 2025Abandon4630NoYes
17200204COMPOSITIONS AND METHODS RELATING TO INHIBITORS OF PRO-INFLAMMATORY CYTOKINES AND CHEMOKINES FOR TREATMENT OF CANCERMarch 2021February 2024Abandon3521NoNo
17274666DRY POWDER FORMULATION OF CAVEOLIN-1 PEPTIDES AND METHODS OF USE THEREOFMarch 2021December 2024Allow4621NoNo
17274721MODIFIED PEPTIDE FRAGMENTS OF CAV-1 PROTEIN AND THE USE THEREOF IN THE TREATMENT OF FIBROSISMarch 2021October 2023Allow3131YesNo
17193832TREATMENTS FOR IMPROVING OR LESSENING IMPAIRMENT OF MITOCHONDRIAL FUNCTIONMarch 2021October 2023Abandon3120NoNo
17272010NOVEL USE OF PEPTIDE FOR INHIBITING FUNCTIONS AND EXPRESSIONS OF MULTIPLE DISEASE BIOMARKERSFebruary 2021March 2024Abandon3631NoNo
17184433USE OF CYCLOSPORINE ANALOGUES FOR TREATING CANCERFebruary 2021June 2024Abandon4041NoNo
17249119PEPTIDES FOR TREATING MUCOSAFebruary 2021October 2022Abandon2011YesNo
17268818STAPLED H2 PYRIN PEPTIDESFebruary 2021April 2024Allow3821YesNo
17267876Self-Assembling Multi-Domain Peptide Based HydrogelsFebruary 2021January 2025Abandon4741YesNo
17170790ORAL PEPTIDE ANTAGONISTS OF MULTIPLE CHEMOKINE RECEPTORS FOR REVERSING LOSS OF SYNAPSES AND DENDRITIC SPINESFebruary 2021February 2024Abandon3630YesNo
17161528METHOD OF OPERATING REDUNDANT STAGGERED DISEASE MANAGEMENT SYSTEMSJanuary 2021May 2024Allow3911YesNo
17157592PHARMACEUTICAL COMPOSITION AND A METHOD FOR ITS MANUFACTUREJanuary 2021March 2023Abandon2620YesNo
17261249PEPTIDE FOR REGULATING REACTIVITY TO SEROTONIN REUPTAKE INHIBITOR BASED ANTIDEPRESSANT, AND USE THEREOFJanuary 2021December 2021Allow1000YesNo
17260934Isolated darobactin A analog compounds and compositions thereof.January 2021September 2022Allow2010YesNo
17258170SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOFJanuary 2021June 2024Allow4241YesYes
17142051CELL PENETRATING SHORT PEPTIDE TAT-HUR-HNS-3 AND APPLICATION THEREOF IN INFLAMMATORY DISEASEJanuary 2021September 2022Abandon2111YesNo
17254234"�-1,3-GLUCAN-PEPTIDE COMPLEX: COMPOSITIONS AND METHODSDecember 2020December 2021Allow1200YesNo
17253774CYCLIC POLYPEPTIDES FOR PCSK9 INHIBITIONDecember 2020July 2023Allow3121YesNo
17251019POLYPEPTIDES, NUCLEIC ACID MOLECULES, COMPOSITIONS, AND RELATED METHODSDecember 2020March 2024Allow3921YesNo
17114443Peptide Docking Vehicle for Targeted Nucleic Acid DeliveryDecember 2020March 2024Allow4012YesNo
17056193CARDIAC-SPECIFIC TARGETING-PEPTIDE (CTP), COMPOSITIONS, AND USES THEREOFNovember 2020August 2023Abandon3321YesNo
17053548PROCESS FOR PREPARATION OF PURE PLECANATIDENovember 2020December 2022Abandon2611NoNo
17053047APPLICATION OF PEDF-DERIVED SHORT PEPTIDES IN TENDON HEALINGNovember 2020May 2022Abandon1811NoNo
17045085PEPTIDE NANOFIBERSOctober 2020March 2024Abandon4121NoNo
17040973GLUCOSE-RESPONSIVE INSULINSeptember 2020November 2023Abandon3801NoNo
17015187TREATMENT OF A HEART DISEASESeptember 2020December 2022Abandon2711NoNo
16969062FIBROBLAST GROWTH FACTOR ANALOGS AND USES THEREOFAugust 2020August 2023Abandon3631YesNo
16989843METHOD FOR BIOCATALYTIC PROTEIN-OLIGONUCLEOTIDE CONJUGATIONAugust 2020April 2024Allow4411YesNo
16938758PEPTIDES FOR TREATING NON-EXUDATIVE MACULAR DEGENERATION AND OTHER DISORDERS OF THE EYEJuly 2020April 2024Abandon4511YesNo
16964566CATIONIC PEPTIDES WITH IMMUNOMODULATORY AND/OR ANTI-BIOFILM ACTIVITIESJuly 2020June 2024Abandon4731NoNo
16962082PEPTIDES AND USES THEREOFJuly 2020June 2024Abandon4731NoYes
16961667ANTI-LEUKEMIC, ANTI-HIV, AND SIALIDASE ACTIVITIES OF ROYAL-JELLY PROTEINSJuly 2020March 2023Abandon3201NoNo
16959533COMPOUNDS AND METHODS FOR REDUCING OR INHIBITING AGGREGATION OF PROTEINS IN A SUBJECTJuly 2020November 2021Allow1700YesNo
16772810PEPTIDES FOR BINDING TO CD44V6 AND USE THEREOFJune 2020October 2021Allow1600YesNo
16770532TREATMENT WITH NMDA RECEPTOR MODULATORSJune 2020March 2022Abandon2201NoNo
16767523USE OF KOR AGONIST IN COMBINATION WITH MOR AGONIST IN PREPARING DRUG FOR TREATING PAINMay 2020June 2022Allow2511NoNo
16629183BIOCONJUGATES WITH CHEMICALLY MODIFIED BACKBONESJanuary 2020September 2023Allow4431YesNo
16684082NEMO COILED COIL MIMICS AND METHODS OF USING SAMENovember 2019September 2023Allow4621YesNo
16603352COVERSIN (OmCl) FOR THE TREATMENT OF AUTOIMMUNE BLISTERING DISEASES: BULLOUS PEMPHIGOID (BP) AND EPIDERMOLYSIS BULLOSA ACQUISITA (EBA)October 2019May 2023Allow4321YesNo
16568913SYNTHETIC BLOOD VESSELS AND USES THEREOFSeptember 2019March 2022Allow3001YesNo
16489302NANOSCALE DRUG CARRIER CAPABLE OF PASSING THROUGH BLOOD-BRAIN BARRIERAugust 2019March 2023Allow4211YesNo
16488180PEPTIDES AND METHODS OF TREATING DYSTROPHY-RELATED DISORDERS USING THE SAMEAugust 2019November 2023Abandon5021YesNo
16472298NEW STAPLED PEPTIDES AND USES THEREOFJune 2019February 2022Allow3101YesNo
16462922CELL-PENETRATING PEPTIDE SEQUENCESMay 2019October 2024Abandon6061YesNo
16334734A METHOD OF DETECTING DISEASED OR DAMAGED TISSUE WITH A PH-TRIGGERED POLYPEPTIDE FLUOROPHORE COMPOSITION.March 2019August 2022Allow4121YesNo
16220685BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2December 2018June 2022Allow4211YesNo
15779237OPTIMIZED RATIOS OF AMINO ACIDS AND SUGARS AS AMORPHOUS STABILIZING COMPOUNDS IN PHARMACEUTICAL COMPOSITIONS CONTAINING HIGH CONCENTRATIONS OF PROTEIN-BASED THERAPEUTIC AGENTSMay 2018April 2023Abandon5921NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CRONIN, JOHN MICHAEL.

Strategic Value of Filing an Appeal

Total Appeal Filings
3
Allowed After Appeal Filing
1
(33.3%)
Not Allowed After Appeal Filing
2
(66.7%)
Filing Benefit Percentile
48.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 33.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner CRONIN, JOHN MICHAEL - Prosecution Strategy Guide

Executive Summary

Examiner CRONIN, JOHN MICHAEL works in Art Unit 1658 and has examined 74 patent applications in our dataset. With an allowance rate of 47.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.

Allowance Patterns

Examiner CRONIN, JOHN MICHAEL's allowance rate of 47.3% places them in the 6% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by CRONIN, JOHN MICHAEL receive 1.58 office actions before reaching final disposition. This places the examiner in the 41% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by CRONIN, JOHN MICHAEL is 33 months. This places the examiner in the 26% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +53.6% benefit to allowance rate for applications examined by CRONIN, JOHN MICHAEL. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 25.0% of applications are subsequently allowed. This success rate is in the 28% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 25.0% of cases where such amendments are filed. This entry rate is in the 25% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 75.0% are granted (fully or in part). This grant rate is in the 90% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.